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in monotherapy and IFN+GA combined, it may be concluded that the first is a 
dominant strategy.
PND30
EcoNomic EvaluatioN of thE trEatmENt comPliaNcE iN PatiENts with 
ParkiNsoN’s DisEasE rEcEivED DiffErENt PrEParatioNs of lEvoDoPa
Ryazhenov V.V., Emchenko I.V.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Objectives: To assess the cost-effectiveness of two conventional combinations 
of levodopa and decarboxylase inhibitors (benserazide or carbidopa) in the treat-
ment of Russian patients with Parkinson’s disease. MethOds: The pharmaco-
economic model was developed based on the data from multicentre randomized 
controlled triple-blind trial (H. Pakkenberg et al., 1976) on the efficacy and toler-
ance of levodopa+benserazide and levodopa+carbidopa in the treatment of patients 
with Parkinson’s disease previously not treated with levodopa. A six-month time 
horizon was adopted in the model. The cost analysis included costs of the original 
preparation of levodopa+benserazide and costs of the available in Russia generic 
preparations of levodopa+carbidopa and considered on-demand antiemetic treat-
ment with domperidone to reduce the incidence of gastrointestinal side effects 
of levodopa. The efficacy of treatment was defined as proportion of patients 
with full compliance to the treatment protocol and proportion of patients with-
out side effects (nausea and vomiting, hyperkinesia). Results: Treatment with 
levodopa+benserazide was associated with significantly lower incidence of patient 
non-compliance (43% as compared to 76% in the levodopa+carbidopa group). Less 
patients in levodopa+benserazide group experienced side effects of levodopa. The 
expenses for antiemetic treatment was 8.7-fold lower in patients treated with 
levodopa+benserazide as compared to those received levodopa+carbidopa. Total 
costs in levodopa+benserazide group were 912,264.90 RUB per 100 patients and 
varied from 682,154.60 RUB to 1,255,226.00 RUB in levodopa+carbidopa groups. The 
cost-effectiveness ratios (CERs) were 15,692.02 RUB and 21,988.11 – 45,866.08 RUB per 
one patient with full compliance to the protocol in the levodopa+benserazide and 
levodopa+carbidopa groups, respectively. The similar results were observed for the 
CERs estimated per one patient without side effects of levodopa. cOnclusiOns: 
The present study has demonstrated that administration of levodopa+benserazide 
is an economically effective strategy in the treatment of Russian patients with 
Parkinson’s disease.
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PharmacoEcoNomic aNalysis of DifErENt aNti-ParkiNsoNiaN Drugs 
usED iN moNoPhEraPy DuriNg Early stagEs of ParkiNsoN DisEasE
Belousov D.Y., Afanasyeva E.V., Efremova E.A.
Pharmacoeconomic research center, Moscow, Russia
Objectives: To evaluate the cost-effectiveness ratio of antiparkinsonian medica-
tion taken as monotherapy in patients with Parkinson’s disease (PD). MethOds: 
A cost-effectiveness analysis (CEA) of therapies including pramipexole ER, prami-
pexole, ropinirole, piribedil and rasagiline has been performed. Direct medical costs 
including costs of medications and treatment of adverse drug effects for 1-year 
therapy of PD have been considered. The clinical effect of selected antiparkinsonian 
medication was assessed in percentage of patients responding to treatment, and 
also by means of the UPDRS II-III scale. All calculations were done in RUR prices 
of 2013 (nominal exchange rate RUR/USD = 30/1). Results: Pramipexole ER has 
the lowest cost-effectiveness ratio (CER) of RUR 57,572 per patient/year respond-
ing to antiparkinsonian therapy. Hence, pramipexole ER was the most effective 
antiparkinsonian preparation studied in pharmacoeconomic terms. Based on cost-
effectiveness ratio, the medications evaluated can be arranged in the following 
order: pramipexole ER (RUR 57,572), pramipexole (RUR 59,548), piribedil (RUR 70,921), 
ropinirole (RUR 71,887), and rasagiline (RUR 91,112). The model results were robust 
to deterministic sensitivity analysis with variable drug costs. Limitations: Absence 
of direct comparative evidence from randomized, double-blind, controlled studies 
makes interpretation of the data difficult. Only short-term studies (up to 24 months) 
were available and hence do not allow to evaluate the influence of pharmacotherapy 
on motor fluctuations as well as other longterm factors. cOnclusiOns: The results 
of the present pharmacoeconomic analysis indicate that pramipexole ER is cost-
effective as first line therapy for the treatment of early stages of Parkinson’s disease 
from a Russian health care perspective. All five formulations evaluated, are well 
below the conditional “willingness to pay ratio” (equal to RUR 1,308607 in 2012). 
Hence, these preparations would qualify for application in the Russian system of 
public reimbursement.
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staNDarD of aNtiEPilEPtic carE BasED oN cliNical PracticE Data
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Objectives: To perform a cost-utility analysis of lacosamide as add-on therapy 
to standard antiepileptic drugs (AEDs) compared to standard AEDs alone based 
on individual patients data derived from actual clinical practice in the Czech 
Republic. MethOds: Based on retrospective data collection of 409 patients with 
epilepsy treated with lacosamide for 6 months in actual clinical practice, we devel-
oped a cost-utility Markov cohort model. The model has 4 basic health states defined 
by number of seizures within 3 months plus 1 state represented by occurrence of 
severe side effects and 1 absorption state; death. Each health state was described 
by utility levels derived from literature. Transition probabilities for the first cycle 
were derived from observational study data and subsequently published literature. 
The model time-horizon was 20 years, 1 cycle length covered 3 months, and a 3% 
discount rate was used for costs and outcomes (Quality adjusted life years (QALYs)). 
Only costs attributed to drug acquisition were calculated, dosing of each AED was 
derived from the retrospective study. We performed probabilistic sensitivity analysis 
(PSA) with 3000 iterations using a willingness to pay (WTP) threshold equal to 3 
Objectives: All recombinant human growth hormones (rhGH) have the same 
molecular structure, therefore providing equal efficacy and safety, and are granted 
the same reimbursement in the Czech Republic (CR). All rhGH are currently 
administered subcutaneously once a day, differing only in applicators. Easypod 
is the only applicator that enables monitoring the dose, time and date of each 
injection and allows feedback control by doctors. The objective was to assess the 
cost-effectiveness of monitored rhGH treatment administered by Easypod with 
an increase in reimbursement of 10% compared to the standard non-monitored 
rhGH administration in CR. MethOds: The interim results (n= 596) of an ongo-
ing multicenter, non-comparative, observational, longitudinal study (ECOS) were 
used to populate deterministic cohort model. The model simulated long-term costs 
and benefits development of rhGH treatment. Evaluation was developed primar-
ily on evidence-based connection (from ECOS) between the monitoring of treat-
ment and patient adherence to the treatment. Increased adherence of monitored 
patients was transferred to the increased effectiveness of the treatment, based on 
published study. Model further transformed the long-term treatment benefits to 
the increased quality of life, using QALY as the target parameter using empirical 
transformation. Costs were expressed from the payer’s perspective. Results: Due 
to an increased adherence in monitored patients, the hypothetical cohort of 10,000 
boys generated 9,517 incremental QALY and CZK1.6 billion incremental costs in a 
lifetime horizon. A hypothetical cohort of 10,000 girls generated 11,504 incremental 
QALY and CZK1.35 billion incremental costs. The average cost per 1 QALY (ICER) is 
approximately CZK157,000 for the patient with GHD. cOnclusiOns: Monitoring 
of the treatment may lead to an increased adherence and more effective treatment 
at relatively low cost, hence being considered cost-effective. Sensitivity analysis 
showed that ICER did not exceed CZK500,000 upon the considered uncertainty.
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Objectives: Multiple sclerosis (MS) causes significant disability and diminished 
quality of life globally. BG-12 is a new oral treatment for relapsing forms of MS 
that is currently approved in the US and Canada and is under regulatory review in 
Europe. A cost-effectiveness model was developed to compare the health economic 
impact of BG-12 against other disease-modifying therapies (DMTs) as first-line 
treatment for relapsing-remitting MS (RRMS) from a Ministry of Health perspec-
tive in Canada. MethOds: A cohort-based Markov model was developed to simu-
late patients’ progression through a series of health states, based on the Kurtzke 
Extended Disability Status Scale (EDSS) over a lime-time horizon. Patients entered 
the model based on a distribution of baseline EDSS scores, from which they could 
either progress/regress to higher/lower EDSS state, or remain in the same state. 
Relapses could occur at any EDSS score. Results from a mixed-treatment comparison 
were used to inform model inputs for disease progression and relapse rates per 
treatment. In addition to the overall discontinuation rates reported in trials, patients 
discontinued treatment on conversion to secondary-progressive MS or reaching 
EDSS 7. Costs included direct medical costs stratified by EDSS score, along with 
relapse, adverse events (AEs), and treatment-related costs. Utilities were accrued 
based on time spent in each EDSS state, adjusted for disutilities associated with 
AEs and caregiver burden. A 5% discount rate was applied. Results: Compared 
with glatiramer acetate, BG-12 yielded 0.396 incremental quality adjusted life years 
(QALYs) at an incremental cost of CAD22,437, resulting in an ICER of CAD56,649. 
Compared with Rebif 44µg, BG-12 resulted in an ICER of CAD10,669. Results were 
consistent across a wide range of one-way and probabilistic sensitivity analy-
ses. cOnclusiOns: Based on traditional cost-effectiveness thresholds in Canada, 
BG-12 can be considered a cost-effective option compared to other first line DMTs.
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Objectives: To assess the cost-effectiveness of the Disease Modifying Treatments 
(DMT), Glatiramer Acetate (GA) and Interferon beta-1a (IFN) in monotherapy alone 
and in combination for the prevention of relapses with established Relapsing–
Remitting Multiple Sclerosis (RRMS) among Spanish patients aged between 18 and 
60 years old. MethOds: A Markov model was developed to represent the transition 
of a cohort of patients over a 10 year period using the perspective of the Spanish 
National Health Service (NHS). The model considered five different health states 
with one-year cycles including without relapse, patients with suspect, non-protocol 
defined and protocol defined exacerbations, as well as the category information lost. 
Efficacy data was obtained from the 3-year CombiRx Study. Costs were reported in 
2013 Euros and a 3%discount rate was applied for health and benefits. Deterministic 
results were presented as the annual treatment cost for the number of relapses. 
A probabilistic sensitivity analysis was performed to test the robustness of the 
model. Results: Deterministic results showed that the expected cost per patient 
was lower when treated with GA (€ 13,843) compared with IFN (€ 15,589) and the 
combined treatment with IFN+GA (€ 21,539). The number of relapses were lower in 
the GA cohort with 3.81 versus 4.08 in the IFN cohort and 4.18 in the cohort treated 
with IFN+GA. Results from probabilistic sensitivity analysis showed that GA has a 
higher probability of being cost-effective than the treatment with IFN or IFN+GA 
for threshold values from € 28,000 onwards, independent of the maximum that the 
Spanish NHS is willing to pay for avoiding relapses. cOnclusiOns: GA showed 
to be a cost-effective treatment option for the prevention of relapses in Spanish 
patients diagnosed with RRMS. When GA in monotherapy is compared with INF 
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over the time horizon of a patient’s lifetime were estimated at 20285, 144194, 299279, 
251255 and 69796 USD for symptom management, Avonex, Betaferon, Rebif and 
CinnoVex, respectively. As a result, the incremental cost per QALY for patients 
receiving Avonex, Betaferon, Rebif and CinnoVex was 607397, 1374355, 1166515 
and 1010429 USD, respectively, when compared with symptom management. The 
results were sensitive to changes in time horizon, disease progression and drug 
costs. cOnclusiOns: DMDs in RRMS patients is associated with increased benefits 
compared with symptom management, albeit at higher costs. Because patients 
receiving Avonex incurred slightly higher QALYs than patients receiving other 
DMDs, treatment with Avonex dominate other DMDs in Iran.
PND36
cost-utility aNalysEs of NatalizumaB vErsus iNtErfEroN BEta-1a 
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sclErosis (rEsrrms) PatiENts iN Brazil
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Objectives: Multiple sclerosis (MS) is a neurologic disease that can dramatically 
affect patients’ quality of life. The aim of this study is to conduct a cost-utility 
analysis of natalizumab (Tysabri®) versus interferon beta-1a 44 mcg (Rebif®) – a 
commonly prescribed 1st line disease modifying therapy – in rapidly evolving severe 
relapsing-remitting MS patients from the Brazilian Public Healthcare System (SUS) 
perspective. MethOds: A Markov model with 20-year time horizon with health 
states based on Expanded Disability Status Scale (EDSS) and disease relapses 
was developed. Since there are no published data evaluating long-term course 
specifically in RESRRMS, it was assumed transition probabilities on EDSS states were 
based on natural history studies in unselected RRMS patients, and relapse prob-
abilities based on a post-hoc analysis of the placebo patients on pivotal natalizumab 
AFFIRM trial. In each monthly cycle, patients can discontinue treatment, remain 
stable, progress to higher EDSS state, experience progressive multifocal leukoen-
cephalopathy (PML) or die. For natalizumab, we assumed efficacy data on disabil-
ity progression and relapse from AFFIRM trial and for interferon beta-1a 44 mcg 
we assumed efficacy data on disability progression and relapse from pivotal trial 
PRISMS. Patients with EDSS score ≥ 7.5 receive best supportive care. Resource use 
and costs were validated by an expert panel and valued using Brazilian public offi-
cial lists (DATASUS and BPS). Costs and outcomes were discounted (5%). Probabilistic 
sensitivity analyses covered variability in efficacy and costs. Results: The use of 
natalizumab was associated with slower EDSS progression and reduced relapse 
burden. The quality-adjusted life years obtained with natalizumab and interferon 
beta-1a 44 mcg were 9.27 and 8.75, and costs were USD119,977 and USD132,446, 
respectively. In the base-case, natalizumab was dominant versus interferon beta-1a 
44 mcg. cOnclusiOns: For a patient with HARRMS, the model shows that natali-
zumab was dominant when compared to interferon beta-1a 44 mcg in the Brazilian 
Public Healthcare System.
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Objectives: To estimate the costs associated with health and social care resource 
use in a UK cohort of people with progressive multiple sclerosis (MS). MethOds: 
Health and social care resource use data were collected prospectively over 33 
months from a cohort of 458 patients with progressive MS enrolled in a UK clinical 
trial (the CUPID Trial). Resource use data are used in combination with unit costs 
(2011 costs) from published UK national sources, and estimates of costs/prices 
where required. Costs for informal (unpaid) care are estimated using equivalent 
hourly home care rates for UK NHS and social care services. Data are presented 
over the 33-month period of follow, and also to allow comparison with other 
studies, against an estimated 6-monthly cost. Regression analyses were used to 
explore the impact on cost estimates from explanatory variables. Results: The 
main component of resource us and costs was informal care provided by friends 
and family, accounting for over 84% of the estimated costs over time. Excluding 
informal care, the most important cost items, within the remaining sub-total of 
costs, were social care (52%), health care services (23%), medications (10%), adapta-
tions (8%), and hospitalisations (6%). From a Payer perspective, the estimated mean 
six-monthly costs of health and social care were £927, but from a broader perspec-
tive the estimated six-monthly cost was £10,737, when private and patient costs 
were included. Regression analyses identified disease severity, as characterised by 
the EDSS, as the main explanatory driver of cost estimates. cOnclusiOns: This 
study presents new information to inform on the impact of progressive multiple 
sclerosis to add to the currently sparse evidence base. Data suggest that costs are 
considerable and fall mainly on patients and carers. The findings also confirm 
the central role of disability status in predicting overall costs associated with the 
impact of progressive MS.
NEurological DisorDErs – Patient-reported outcomes & Patient Preference 
studies
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trEatmENt aDhErENcE aND costs iN multiPlE sclErosis: a NarrativE 
rEviEw of thE litEraturE
Paz S., Comellas M., Lizán L.
Outcomes 10, Castellon, Spain
Objectives: To appraise the literature relating adherence and other patients’ 
reported outcomes (PROs) to Multiple Sclerosis (MS) costs. MethOds: Electronic 
databases [MedLine/PubMed, Google Scholar, Congress proceedings] were searched 
to identify publications analyzing MS costs related to adherence, persistence, sat-
times GDP per capita (43,000 EUR) in the Czech Republic. Results: Over a 20 year 
time-horizon, add-on lacosamide generated 11.47 QALYs and costs 33,439 EUR (per 
patient), whereas standard AEDs alone provided 11.09 QALYs and costs 22,916 EUR 
(per patient), respectively. The base-case ICER was calculated as 27,692 EUR/QALY. 
Based on the PSA and its cost-effectiveness acceptability curve (CEAC) we calculated 
that add-on lacosamide has a probability of cost-effectiveness at 43,000 EUR per 
QALY gained of 80.2% compared to standard AEDs alone. cOnclusiOns: Based 
on data from clinical practice lacosamide as add-on treatment in patients with 
partial-onset seizures is cost-effective under the WTP threshold implicitly applied 
in the Czech Republic.
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cost EffEctivENEss of PharmacogENEtic scrEENiNg Prior to 
iNitiatioN of carBamazEPiNE trEatmENt for EPilEPsy
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Objectives: Carbamazepine (CBZ) is a widely-used, first-line treatment in epilepsy. 
However, CBZ is associated with hypersensitivity adverse drug reactions (ADRs) 
ranging from mild rash such as maculopapular exanthema, to hypersensitivity 
syndrome, Steven-Johnson syndrome and toxic epidermal necrolysis (TEN). TEN is 
associated with a mortality rate of up to 30%. The presence of the HLA-A*3101 allele 
is associated with an increased risk of CBZ-induced hypersensitivity reactions [OR 
9.1, 95% CI, 4.0 to 20.7]. HLA-A*3101 is present in 2% - 5% of populations of Northern 
European descent. We aim to investigate the cost effectiveness of pharmacoge-
netic testing for HLA-A*3101prior to initiation of CBZ treatment in patient with 
epilepsy. Patients testing positive for the allele are prescribed an alternative antie-
pileptic drug, lamotrigine. MethOds: A decision analytic model was developed to 
represent the first three months post initiation of anti-epileptic drug, to cover the 
period when the majority of severe ADRs manifest. A Markov model (cycle length 
1 year) was used to simulate costs (from the perspective of the NHS in the UK) and 
utilities incurred in subsequent years. This enables modelling of costs and disutili-
ties from long term sequelae of severe ADRs as well as the effectiveness of treatment 
in terms of remission of seizures. Transition probabilities, costs and utilities were 
sourced from patient level data from the SANAD trial [Lancet 369(9566):1000-15] 
and relevant literature. Results: Compared with no pharmacogenetic testing, and 
prescribing CBZ for all patients, the test results in an incremental cost effective-
ness ratio of £26,684 per QALY gained. The probability that testing is cost-effective 
at a threshold of £30,000 per QALY is 0.55, and the cost of preventing a single ADR 
is £35962. cOnclusiOns: Pharmacogenetic testing for HLA-A*3101 prior to treat-
ment with CBZ might be cost-effective for populations of North European descent.
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1Ipsen Pharma, Sant Feliu de Llobregat, Spain, 2University of Barcelona, Barcelona, Spain, 
3Oblikue Consulting, Barcelona, Spain, 4Hospital Universitario La Paz, Madrid, Spain
Objectives: Botulinum toxin type A (BoNT-A) is considered one of the treatments 
of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy 
(CP) patients, two years of age or older by decreasing hyperactivity and increasing 
muscle tone in patients. The aim was to compare the cost of Botox® (Allergan) and 
Dysport® (Ipsen), considering the administered dose per weight (U/kg) in child 
patients with equinus foot CP related. MethOds: We performed an observational, 
longitudinal and retrospective study with data from clinical records from December 
1995 to October 2012. Records included patients younger than 18 years old with 
spasticity treated with BoNT-A at the Pediatric Neurology Service of the Hospital of 
La Paz (Madrid), with recorded birth and visit dates, weight and dose by muscle. Cost 
analysis only evaluated four muscle groups (pronator teres, adductor, semitendi-
nosus and triceps surae) including only direct costs (drug and visit costs). We used 
bootstrap as sensitivity analysis to assess the robustness of results. Costs were in 
euros 2013. Results: A total of 895 patients treated with BoNT-A for spasticity (543 
treated with Botox®, 292 with Dysport® and 60 with both) were included. Baseline 
characteristics and follow-up were similar in both groups. Patients had an average 
dose infiltrated per visit of 5.44 U/kg (SD 2.17) for Botox® and 14.73 U/kg (SD 5.26) 
for Dysport®, and average yearly visits of 3.71 for Botox® and 3.46 for Dysport®. The 
annual total cost per patient was 850 € for Botox® and 636 € for Dysport®. Of these 
total costs, annual visit costs of 362 € for Botox® and 347 € for Dysport®, and annual 
drug costs were 488 € for Botox® and 289 € for Dysport®. cOnclusiOns: Based on 
the real-world management of pediatric spasticity patients with BoNT-A observed 
in our study, Dysport® could reduce annual total costs per patient.
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cost-utility aNalysis of DisEasE-moDifyiNg Drugs iN rElaPsiNg-
rEmittiNg multiPlE sclErosis iN iraN
Imani A., Golestani M., Tabrizi J.S., Janati A.
Tabriz Medical University, Tabriz, Iran
Objectives: Disease-modifying drugs (DMDs) are a significant expenditure for 
treating multiple sclerosis. However, assessment of the cost-utility of DMDs com-
pared with symptom management in the presence of long-term data has been lim-
ited. To assess the lifetime cost-utility from the Iranian health care perspectives of 4 
disease-modifying drugs relative to symptom management alone in patients with 
relapsing-remitting multiple sclerosis using evidence from long-term published 
studies. MethOds: A Markov model was developed with patients transitioning 
through health states based on Kurtzke expanded disability status scale (EDSS). 
Patient costs included drug costs, other medical and lost worker productivity costs. 
Patient quality of life was considered in the form of utilities. Costs were valued in 
2011 USD, and costs were discounted at 7.2%per annum. Various parameters and 
assumptions were tested in sensitivity analyses. Results: Total costs per patient 
